Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Reporting Date: February 23, 2026 (Event Date: February 27, 2026)
Context: The filing reports the entry into a new material definitive agreement for an at-the-market (ATM) equity offering and the termination of a prior ATM agreement.
Key Financial Metrics and Capital Structure
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The financial data provided relates exclusively to capital raising activities:
- New Offering Capacity: Up to $100,000,000 of Common Stock under the new ATM Agreement with Jefferies LLC.
- Commission Rate: Up to 3.0% of gross proceeds from sales under the new agreement.
- Terminated Offering Capacity: The prior ATM agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC covered up to $7,350,000.
- Expense Reimbursements: The Company agreed to reimburse Jefferies for legal fees up to $100,000, plus $25,000 for annual 10-K filings and $15,000 for quarterly 10-Q or specific 8-K filings.
Material Changes Versus Prior Period
The primary material change is the replacement of the equity sales agent and the expansion of the authorized offering size:
- Agent Change: Terminated the Prior ATM Agreement (dated July 3, 2024) with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC.
- New Agreement: Entered into a new Open Market Sale Agreement with Jefferies LLC on February 27, 2026.
- Capacity Increase: The new offering capacity ($100,000,000) is significantly larger than the terminated offering capacity ($7,350,000).
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company retains full discretion over the sale of shares, including the number of shares, timing, and price parameters. There is no obligation to sell any shares, and the Company may suspend the program at any time. Jefferies is not obligated to purchase any shares on a principal basis.
Risks and Contingencies:
- Registration Effectiveness: The new offering is contingent upon the effectiveness of the Form S-3 Registration Statement (File No. 333-293864). The Company provides no assurance that the statement will become effective or remain effective.
- Dilution: Sales of Common Stock under the ATM program will result in dilution to existing shareholders.
- Market Conditions: Sales are subject to market conditions and the Company's instructions regarding minimum prices and daily volume limits.
Key Facts for Investor Verification
- Verify the effectiveness status of the new Form S-3 Registration Statement (File No. 333-293864) filed on February 27, 2026.
- Monitor future 8-K filings for actual sales volumes and proceeds generated under the new Jefferies ATM agreement.
- Review the Company's cash position to assess the necessity of the $100 million capital raise.
- Confirm the total number of shares outstanding to calculate potential dilution from the new offering.